Benitec Biopharma Q3 2023 Earnings Report $12.00 -0.77 (-6.03%) (As of 12:32 PM ET) Earnings HistoryForecast Benitec Biopharma EPS ResultsActual EPS-$2.72Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABenitec Biopharma Revenue ResultsActual Revenue$0.05 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABenitec Biopharma Announcement DetailsQuarterQ3 2023Date5/15/2023TimeN/AConference Call ResourcesBNTC Earnings History URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Benitec Biopharma Earnings HeadlinesBenitec Biopharma (NASDAQ:BNTC) Coverage Initiated at HC WainwrightDecember 18 at 1:55 AM | americanbankingnews.comBenitec Biopharma (NASDAQ:BNTC) Appoints New Chief Operating Officer and Makes Changes to Executive Officers' Roles and CompensationDecember 17 at 2:05 AM | americanbankingnews.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.December 18, 2024 | Brownstone Research (Ad)Benitec Biopharma (NASDAQ:BNTC) Earns Outperform Rating from Analysts at Robert W. BairdDecember 16 at 1:53 AM | americanbankingnews.comBenitec Biopharma Shakes Up Management TeamDecember 14, 2024 | marketwatch.comBaird Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationDecember 13, 2024 | msn.comSee More Benitec Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Benitec Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Benitec Biopharma and other key companies, straight to your email. Email Address About Benitec BiopharmaBenitec Biopharma (NASDAQ:BNTC), a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.View Benitec Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
